Andreas Roos
Adjunct Professor, University of Ottawa
Scientific Officer, Department of Neuropediatrics, University Hospital Essen
Email AndreasAndreas completed his PhD in 2009 with Professor Jan Senderek in the Neurogenetics group of the Institute of Human Genetics of RWTH-Aachen University in Germany, where his thesis focused on the elucidation of molecular and biochemical mechanisms in autosomal recessive Charcot-Marie-Tooth neuropathies. Following a postdoc in the Institute of Molecular Biology and Medical Biochemistry at the University of Saarland, he became a junior group leader at the Institute of Neuropathology at RWTH-Aachen University. Subsequently, he took on the role of group lead of the Tissue Omics group at the Leibniz Institute of Analytical Science (ISAS) in Dortmund, focusing on applied proteomics toward a better understanding of the molecular genesis of neuromuscular diseases. In 2015 he moved to Newcastle upon Tyne (UK) as Scientific Officer in the John Walton Muscular Dystrophy Research Centre under Professor Hanns Lochmüller. After moving to Essen in Germany in 2018 to become Scientific Officer in the University Hospital Essen’s Department of Neuropediatrics, together with Prof. Ulrike Schara he was awarded a 2.9M Euro grant from the European Regional Development Fund for NMD-GPS, a major interdisciplinary multi-omics project aiming to improve the diagnostic management of patients with neuromuscular diseases as well as to group these diseases according to their underlying pathomechanisms.
In 2019 Andreas was awarded an adjunct professorship at the University of Ottawa, where he will be an external/visiting member of the Lochmüller Lab team, teaching applied proteomics in the context of neuromuscular diseases, co-supervising students and continuing his many close scientific collaborations with the group.
In 2023, Andreas received the World Muscle Society’s President’s Prize for Emerging Myologist of the Year.
Read more about Andreas
Recent publications
Labella, B, Leonard-Louis, S, Lacene, E, Beuvin, M, Chanut, A, Madelaine, A et al.. Drug-induced autophagic myopathies: Exploring pathophysiology with immunolabelling and proteomics. J Neuropathol Exp Neurol. 2026. PMID:42570312
Holland, SH, Carmona-Martinez, R, Hentschel, A, Derksen, A, O'Connor, K, O'Neil, D et al.. Hexosamine Pathway Disruption by GFPT1 Loss Drives Coordinated Defects in Glycosylation, Autophagy, and Trafficking. Biomolecules. 2026.16 (7) PMID:42509760
Manis, C, Pertusati, F, Morewood, J, Roos, A, Kleefeld, F, Onali, M et al.. Bis(monoacylglycero)phosphate (BMP) as a circulating biomarker of lysosomal dysfunction in GNE myopathy. Clin Chim Acta. 2026.593 121244 PMID:42501775
Capece, G, Di Feo, MF, Melnik, E, Dadali, E, Markova, T, Verloes, A et al.. Beyond distal arthrogryposis: refining the phenotypic landscape of PIEZO2-related disorders. Brain. 2026. PMID:42496149
Malaichamy, S, Polavarapu, K, Thompson, R, Idoux, R, Spendiff, S, Karcagi, V et al.. Systematic reanalysis of next-generation sequencing data in 101 neuromuscular disorder families enhances diagnostic yield, reveals intronic variants, and identifies a novel disease gene. J Neurol. 2026.273 (8) PMID:42474733
Georgiou, E, Kagiava, A, Hentschel, A, Sargiannidou, I, Papacharalampous, R, Stavrou, M et al.. A dose-escalation and safety gene therapy study in a model of CMT4C neuropathy. Gene Ther. 2026. PMID:42120546
Oeztuerk, M, Walli, S, Muhmann, D, Choueiri, C, Dobelmann, V, Abicht, A et al.. The p.(Leu97Ile) variant expands the genetic landscape of NEFL-associated Charcot-Marie-tooth neuropathies. Hum Mol Genet. 2026.35 (7) PMID:42017539
Kleefeld, F, Teran Gamboa, J, Pinal-Fernandez, I, Preusse, C, Nelke, C, Goebel, HH et al.. Brachio-cervical inflammatory myopathy: multilevel clinical, histopathological and multi-omic analyses of a syndrome variably associated with systemic sclerosis. Acta Neuropathol. 2026.151 (1) PMID:41934478
Langer, HT, Gilmore, NK, Hayden, CMT, Roux, J, Bariohay, B, Rouquet, T et al.. Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans. Cell Rep Med. 2026.7 (3)102665 PMID:41850248
Pauper, M, Kölbel, H, Karakesisoglou, I, Schänzer, A, Böhm, J, Thompson, R et al.. A muscular dystrophy associated with bi-allelic LEMD2 variants: Expanding the genotype of nuclear envelopathies. Brain Pathol. 2026.36 (4)e70082 PMID:41776713
Bertino, F, Zanin Venturini, DI, Grasso, E, Kopecka, J, Salio, C, Gnutti, B et al.. Mitochondrial energetic failure underlies FLVCR1-related sensory neuropathy. Commun Biol. 2026.9 (1) PMID:41691085
Daya, NM, Schänzer, A, Hentschel, A, Kienitz, MC, Sellung, D, Suedkamp, N et al.. Unveiling FLNC variants: iPSC-derived myogenic cells as a model to study disease mechanisms. Skelet Muscle. 2026.16 (1) PMID:41680819
See more on PubMed